Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer
The purpose of this study is to determine whether Sunitinib and Docetaxel is effective in the treatment of advanced gastric cancer patients who had prior chemotherapy with fluoropyrimidine and platinum.
Advanced Gastric Cancer
DRUG: Docetaxel + Sunitinib|DRUG: Docetaxel only
time to progression, every 6 weeks
Response rate, 12 months|Overall survival, 12 months|Progression free survival, 12 months
This is a randomized phase II trial of Sunitinib and Docetaxel in advanced gastric cancer patients who had prior chemotherapy with Fluoropyrimidine and Platinum.